Hyaluronan-rich extracellular matrix (HA-rich ECM)

The **extracellular hyaluronic acid (hyaluronan) matrix** refers to regions of tissue extracellular matrix (ECM) that are particularly rich in hyaluronan (HA), a large linear glycosaminoglycan that forms hydrated, gel-like networks in the extracellular space. Unlike classical targets such as receptors, enzymes, or transporters, the HA-rich matrix is a **structural and functional component** of tissues—providing hydration, elasticity, and a framework for cell migration and proliferation[1][2][4][6]. HA interacts with cell-surface receptors (for example, CD44) to mediate a wide range of cellular responses, including wound healing, inflammation, and tissue morphogenesis[1][2][4]. Changes in the composition and physical properties of the HA matrix are implicated in a variety of diseases, such as cancer, fibrosis, osteoarthritis, and neurological disorders[1][2][4][7][8]. While certain therapeutic interventions (such as hyaluronidase enzymes or exogenous HA) act on or use the HA matrix, the matrix itself is not a discrete molecular "target" in the pharmacological sense, but rather a complex and dynamic tissue structure[2][4][8]. "Extracellular hyaluronic acid matrix" is a descriptor for a **tissue or structural feature**, not a defined molecular entity such as a receptor, enzyme, or transporter. It cannot be characterized by a canonical single gene, protein, or specifically druggable target. If you are seeking pharmacological targets, the relevant molecules would be "Hyaluronan synthases," "Hyaluronidases," or the principal HA receptors such as "CD44" or "RHAMM" (HMMR). If you need data for these *molecular targets* (e.g., "CD44" or "Hyaluronan synthase 2"), please specify.

Other names

Hyaluronan extracellular matrixHyaluronic acid extracellular matrixHA matrixExtracellular hyaluronan matrix

Hyaluronidase degrades the HA matrix, reducing viscosity and ECM integrity Exogenous HA restores lubrication, hydration, structural support